|
|
Article: MannKind's Inhaled Insulin In Phase III Efficacy Studies.
- Article from:
- BIOWORLD Today
- Article date:
- March 7, 2006
- Author:
CopyrightCOPYRIGHT 2006 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Aaron Lorenzo, Washington Editor
MannKind Corp. is well under way with the pivotal development of its inhaled insulin product, Technosphere Insulin (TI), with two additional Phase III studies now started.
Patient enrollment began in the trials to evaluate the product's efficacy by assessing changes in both HbA1c levels and blood glucose levels after a standardized meal. Also, new data soon will come from two recently completed Phase III trials, a three-month study in Type I diabetes patients and a six-month study in Type II diabetes patients.
Noting the Valencia, Calif.-based company's "very extensive program" for TI, Peter Richardson, ...